These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 34463922)
21. Medical Costs Associated with Insomnia Treatment with Suvorexant Monotherapy in Japan: Results from a Retrospective Cohort Study Using a Large-Scale Claims Database. Uchiyama M; Ito K; Okumura Y; Yi J; Crawford B; Abe M Drugs Real World Outcomes; 2022 Jun; 9(2):219-229. PubMed ID: 35129832 [TBL] [Abstract][Full Text] [Related]
22. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752 [TBL] [Abstract][Full Text] [Related]
23. A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women. Rahman SA; Nathan MD; Wiley A; Crawford S; Cohn AY; Harder JA; Grant LK; Erickson A; Srivastava A; McCormick K; Bertisch SM; Winkelman JW; Joffe H Sleep; 2022 Mar; 45(3):. PubMed ID: 35022783 [TBL] [Abstract][Full Text] [Related]
24. Economic burden of comorbid insomnia in 5 common medical disease subgroups. Wickwire EM; Juday TR; Kelkar M; Heo J; Margiotta C; Frech FH J Clin Sleep Med; 2023 Jul; 19(7):1293-1302. PubMed ID: 37394794 [TBL] [Abstract][Full Text] [Related]
25. Suvorexant: something new for sleep? Reddy A; Puvvada SC; Kommisetti S; El-Mallakh RS; Lippmann S Acta Neuropsychiatr; 2015 Feb; 27(1):53-5. PubMed ID: 25397996 [TBL] [Abstract][Full Text] [Related]
26. Fall Risk, Healthcare Resource Use, and Costs Among Adult Patients in the United States Treated for Insomnia with Zolpidem, Trazodone, or Benzodiazepines: A Retrospective Cohort Study. Amari DT; Juday TR; Frech FH; Wang W; Gor D; Atkins N; Wickwire EM Adv Ther; 2022 Mar; 39(3):1324-1340. PubMed ID: 35072889 [TBL] [Abstract][Full Text] [Related]
27. Real-world evidence of the safety and efficacy profile of suvorexant in elderly patients with insomnia: a sub-analysis of the post-marketing drug-use results survey in Japan. Takeuchi Y; Sano H; Asai Y; Miyazaki M; Iwakura M; Maeda Y Curr Med Res Opin; 2020 Mar; 36(3):465-471. PubMed ID: 31793350 [No Abstract] [Full Text] [Related]
28. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population. Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096 [TBL] [Abstract][Full Text] [Related]
29. The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data. Waters HC; Stellhorn R; Touya M; Fitzgerald H; Bhattacharjee S; Citrome L J Med Econ; 2023; 26(1):316-325. PubMed ID: 36780296 [TBL] [Abstract][Full Text] [Related]
30. Can the Orexin Antagonist Suvorexant Preserve the Ability to Awaken to Auditory Stimuli While Improving Sleep? Drake CL; Kalmbach DA; Cheng P; Roth T; Tran KM; Cuamatzi-Castelan A; Atkinson R; Singh M; Tonnu CV; Fellman-Couture C J Clin Sleep Med; 2019 Sep; 15(9):1285-1291. PubMed ID: 31538599 [TBL] [Abstract][Full Text] [Related]
31. Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Kishi T; Matsunaga S; Iwata N PLoS One; 2015; 10(8):e0136910. PubMed ID: 26317363 [TBL] [Abstract][Full Text] [Related]
32. Suvorexant: a novel therapy for the treatment of insomnia. Howland RH J Psychosoc Nurs Ment Health Serv; 2014 Oct; 52(10):23-6. PubMed ID: 25291725 [TBL] [Abstract][Full Text] [Related]
33. The association between insomnia severity and healthcare and productivity costs in a health plan sample. Sarsour K; Kalsekar A; Swindle R; Foley K; Walsh JK Sleep; 2011 Apr; 34(4):443-50. PubMed ID: 21461322 [TBL] [Abstract][Full Text] [Related]
34. Effects of suvorexant on sleep apnea in patients with heart failure: A protocol of crossover pilot trial. Shitara J; Kasai T; Akihiro S; Yatsu S; Matsumoto H; Suda S; Ogita M; Yanagisawa N; Fujibayashi K; Nojiri S; Nishizaki Y; Ono N; Suwa S; Daida H J Cardiol; 2019 Jul; 74(1):90-94. PubMed ID: 30737183 [TBL] [Abstract][Full Text] [Related]
36. Insomnia-related comorbidities and economic costs among a commercially insured population in the United States. Pollack M; Seal B; Joish VN; Cziraky MJ Curr Med Res Opin; 2009 Aug; 25(8):1901-11. PubMed ID: 19530979 [TBL] [Abstract][Full Text] [Related]
37. Effect of Suvorexant vs Placebo on Total Daytime Sleep Hours in Shift Workers: A Randomized Clinical Trial. Zeitzer JM; Joyce DS; McBean A; Quevedo YL; Hernandez B; Holty JE JAMA Netw Open; 2020 Jun; 3(6):e206614. PubMed ID: 32484552 [TBL] [Abstract][Full Text] [Related]
38. Real-World Preventive Effects of Suvorexant in Intensive Care Delirium: A Retrospective Cohort Study. Izuhara M; Izuhara HK; Tsuchie K; Araki T; Ito T; Sato K; Miura S; Otsuki K; Nagahama M; Hayashida M; Hashioka S; Wake R; Kimura T; Tsumoto S; Saito Y; Inagaki M J Clin Psychiatry; 2020 Oct; 81(6):. PubMed ID: 33027560 [TBL] [Abstract][Full Text] [Related]
39. Real-world antifibrotic treatment patterns in patients with idiopathic pulmonary fibrosis: retrospective analyses of two large healthcare administrative databases in the United States. Qiu Y; Zhu J; Chopra P; Elpers B; Dieyi C; Byrne C; Tang J; Wang Y; Govindaraj K; Fischer A Ther Adv Respir Dis; 2024; 18():17534666241280704. PubMed ID: 39418137 [TBL] [Abstract][Full Text] [Related]
40. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia. Owen RT Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]